Pay in 4 interest-free payments of $6.86 Learn more
Ships within 48 hours · Estimated delivery Oct 10 - Oct 15
Clinical evidence also suggests potential advantages in wound healing
Summary: Retatrutide is an investigational triple receptor agonist (GLP-1, GIP, and glucagon) showing promising early weight-loss and metabolic data in Phase 2 trials, but it is not yet approved in the UK and carries notable side effects and safety uncertainties
Your health and weight loss path is unique
Dose adjustments of these agents are likely to be necessary under medical supervision
Body-Mass Index in 2.3 million adolescents and cardiovascular death in adulthood
US$ 26.25
US$ 26.62
US$ 27.20
US$ 28.24
US$ 24.44
US$ 21.31
US$ 27.00
US$ 22.39
US$ 20.21
US$ 29.75
US$ 29.00
US$ 20.75
US$ 20.27
US$ 24.23
